TiGenix obtains manufacturing license for European production facility
"I'd like to commend our manufacturing team responsible for building and validating our production plant in record time and passing the inspection of the Dutch regulatory authorities with flying colors," said Eduardo Bravo, CEO of TiGenix. "Our state-of-the-art manufacturing site is unique in Europe as it is 100% geared towards the production of innovative cell therapy products. It provides us with crucial manufacturing capabilities to support the anticipated growth in demand for ChondroCelect for cartilage repair, and has sufficient capacity for the production of our advanced stem cell therapy products."
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.